Streamlining Psychiatry Surescripts Integration for Expedited Medication Access

Klivira's psychiatry Surescripts integration empowers behavioral health providers to automate and accelerate prior authorizations for critical medications, reducing administrative burden and improving patient access.

For revenue cycle directors and prior authorization coordinators in psychiatric practices, managing medication PAs is a significant challenge. The complexity of specialty drugs, controlled substances, and step-therapy requirements can delay vital treatments. Klivira leverages Surescripts ePA to streamline these workflows, ensuring faster turnaround times for pharmacy benefit authorizations.

The Critical Need for Surescripts ePA in Psychiatry

Psychiatric care often relies on specific, high-cost, or controlled medications that frequently trigger prior authorization. These include atypical antipsychotics, ADHD stimulants, and novel treatments like esketamine. Manual submission processes for these drugs can lead to significant delays, impacting patient adherence and clinical outcomes. Surescripts ePA provides a standardized, electronic pathway to submit these requests, crucial for time-sensitive mental health interventions.

Key Psychiatric Medications Benefiting from Surescripts ePA

Atypical antipsychotics (e.g., long-acting injectables like paliperidone palmitate, aripiprazole long-acting)
Stimulants (controlled substances for ADHD management)
Esketamine (Spravato) and other REMS-restricted medications
Specialty drugs for tardive dyskinesia (e.g., valbenazine, deutetrabenazine)
Certain buprenorphine formulations for opioid use disorder
Injectable medications such as naltrexone (Vivitrol)

Automating Medication PA Workflows with Klivira's Surescripts Integration

Klivira integrates directly with your EMR via SMART on FHIR, extracting necessary patient and clinical data to populate Surescripts ePA requests. This automation minimizes manual data entry, reduces errors, and ensures that documentation for conditions like diagnosis confirmation, prior medication trials, and REMS compliance (for drugs like esketamine) is accurately submitted. Our platform supports the NCPDP SCRIPT standard for efficient electronic communication with Pharmacy Benefit Managers (PBMs).

Typical Documentation Requirements for Psychiatric Medication ePA

DSM-5-TR diagnosis and severity documentation (e.g., PHQ-9, GAD-7 scores)
Confirmation of prior oral medication trials (for specialty injectables or TMS-related drug trials)
REMS program enrollment and administration site documentation for restricted-dispensing drugs (e.g., esketamine, brexanolone)
Medical necessity justification correlating medication to treatment plan
Prescriber attestation of adherence to clinical guidelines where applicable

Addressing Psychiatry's Unique PA Challenges Through Automation

Psychiatric practices face unique workflow constraints, including the time-sensitive nature of many medication decisions and the specific requirements for controlled or restricted-dispensing drugs. Klivira's Surescripts integration is designed to navigate these complexities, flagging potential step-therapy denials and ensuring all required documentation is present for timely submission. This proactive approach helps mitigate common denial reasons such as insufficient prior trial documentation.

Enhanced Compliance and Efficiency for Behavioral Health

By centralizing prior authorization for pharmacy benefits through Surescripts, Klivira helps maintain compliance while significantly boosting operational efficiency. This allows psychiatric care teams to focus on patient care rather than administrative tasks, improving access to essential treatments and supporting better patient outcomes. Discuss considerations with your compliance team regarding ePHI handling and HIPAA guidelines.

Frequently asked questions

Which specific psychiatric medications can be authorized via Surescripts ePA?

Surescripts ePA is primarily used for pharmacy benefit medications. This includes a wide range of psychiatric drugs such as atypical antipsychotics, ADHD stimulants, specialty injectables (e.g., paliperidone palmitate, naltrexone), and REMS-restricted medications like esketamine. It streamlines the process for drugs that frequently require prior authorization.

How does Klivira's Surescripts integration handle documentation for complex psychiatric cases?

Klivira automates the extraction of relevant clinical data from your EMR, including DSM-5-TR diagnoses, severity scores (e.g., PHQ-9), and documented prior medication trials. For drugs like esketamine, it helps ensure that REMS program enrollment and administration site details are included, reducing manual effort and improving submission accuracy.

Can Surescripts ePA be used for psychiatric inpatient or residential treatment authorizations?

No, Surescripts ePA is specifically for pharmacy benefit medications. Prior authorizations for inpatient psychiatric admissions, partial hospitalization (PHP), intensive outpatient (IOP), or residential treatment are typically submitted via medical benefit channels, such as X12 278 transactions or payer-specific portals, not through Surescripts.

What are common denial reasons for psychiatric medication PAs that Surescripts integration helps address?

Common denial reasons include insufficient documentation of prior medication trials (step therapy), missing clinical justification, or incomplete REMS program information for restricted drugs. Klivira's automation, leveraging Surescripts, ensures that these critical data points are captured and submitted accurately, proactively mitigating such denials.

How does Klivira ensure data security and HIPAA compliance with Surescripts ePA?

Klivira is built with robust security measures to protect ePHI during data extraction from EMRs and transmission to Surescripts. Our platform adheres to industry best practices and standards, ensuring HIPAA compliance throughout the prior authorization workflow. We recommend discussing specific data handling protocols with your organization's compliance team.